IMV News and Press, IMV Inc. From 07/14/20

Gainers:  INmune Bio (NASDAQ: INMB ) +114% . More news on: INmune Bio, Inc., Perceptron, Inc., Rigel Pharmaceuticals, Inc., Stocks on the move, , Read more ...

3 COVID Penny Stocks To Watch After Latest News It’s earnings season and the markets are likely set for more volatility. Throw on more coronavirus cases and there could be an interesting scenario right now. The long and short of it is that penny stocks have seen quite the trickledown ...

IMV (NASDAQ: IMV ) +162%   rallies on COVID-19 vaccine progress. More news on: IMV Inc., VolitionRx Limited, INmune Bio, Inc., Stocks on the move, , Read more ...

Thinly traded micro cap IMV (NASDAQ: IMV ) jumps  166%  premarket on robust volume in response to its announcement that Health Canada has signed off on the design of a Phase 1 clinical trial evaluating the safety and immunogenicity of two dose levels (25μg or 50μg...

Received agreement with Health Canada on Phase 1 clinical study design protocol which also includes older patients of 56 years and above Completed cGMP formulation and manufacturing process development for clinical trials Ready and prepared for Clinical Trial Application submissio...

IMV Inc. (“ IMV ” or the “ Company ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced that in order to maintain the remainder of its at-the-market facility announced on March 18, 2020 under its new Canadian base shelf prospectus...

IMV Inc. (“ IMV ” or the “ Company ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today announced that, in order to replace its prior base ...

IMV Inc. (“ IMV ” or the “ Company ”) (Nasdaq: IMV; TSX: IMV), is pleased to announce that Institutional Shareholder Services Inc. (“ ISS ”) and Glass, Lewis & Co., LLC (“ Glass Lewis ”), have recommended that shareholders vote FOR a...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today announced that company management will be presenting at the Raymond James' Human Health Innovation Conferenc...

IMV (NASDAQ: IMV ) jumps 9.4%  in premarket trading after results from its Phase 2 study of DPX-Survivac immunotherapy in advanced recurrent ovarian cancer showed prolonged durable clinical responses alongside favorable tolerability. More news on: IMV Inc., Healthcare stocks news, St...